ea0056p724 | Clinical case reports - Pituitary/Adrenal | ECE2018
Anderson Cian
, Griffin James
, McKenna Susan
, Santos Ana
, Westrup Jenny
, Kelleher Fergal
, Griffin Margaret
Ipilimumab (an anti-CTLA-4 antibody) treatment has been associated with Immune Related Adverse Events (iRAEs) of the endocrine system. However the frequency of iRAEs in programmed cell death (PD-1) receptor agent use is incompletely characterised, though initial studies report an incidence of 0.5%. We present a case of Pembrolizumab-induced hypophysitis in a 47 yo. male with melanoma. Presenting in 2007 with an initial diagnosis of melanoma, with lymph node recurrence in 2013....